AmgenvsZenas BioPharma

AMGN and ZBIO stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

ZBIO

Zenas BioPharma, Inc.

$23.85

Value $1.6B

-4.75%
ZBIO's page

Amgen (AMGN) has a market value of $235B and Zenas BioPharma (ZBIO) $1.6B. Over the last year, with dividends, AMGN moved +31.5% and ZBIO -35.8%. Dividend yield: AMGN 2.31%, ZBIO none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$235B

    ZBIO$1.6B

    AMGN is 145 times ZBIO

  • Revenue, 12 months

    AMGN$38.9B

    ZBIO$11M

    AMGN is 3,537 times ZBIO

  • Net income, 12 months

    AMGN$9.4B

    ZBIO-$542M

  • Operating margin

    AMGN32.4%

    ZBIO-4,785.5%

    4,817.9 points apart

  • ROIC

    AMGN16.2%

    ZBIO-102.7%

    118.9 points apart

  • P/E

    AMGN25.0

    ZBIO–

  • Dividend yield

    AMGN2.3%

    ZBIO0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+31.5%

ZBIO-35.8%

50100DecFebAprJunAugOct
Returns by period
PeriodAMGNWith dividendsZBIOWith dividends
1 year since November 19, 2025+31.5%Price +27.2%-35.8%Price -35.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenZBIOZenas BioPharma

Valuation

AMGNZBIO
Valuation
Price$435.64$23.85
Market value$235B$1.6B
Enterprise value (EV)$276B$1.2B
P/E25.0–
P/E, 5-year median23.0–
P/B16.47.6
EV/EBIT21.9–
Free cash flow yield4.1%–

Results and growth

AMGNZBIO
Results and growth
Revenue, 12 months$38.9B$11M
Net income, 12 months$9.4B-$542M
Free cash flow, 12 months$9.6B-$243M
Earnings per share, 12 months$17.25-$10.05
Revenue growth, year on year10.0%100.0%
Revenue growth a year, past+7.6%over 5 years-55.3%over 2 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNZBIO
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%-4,785.5%
Net margin24.1%-4,925.5%
ROIC16.2%-102.7%
ROE87.8%-219.6%

Balance sheet

AMGNZBIO
Balance sheet
Cash$13.2B$647M
Total debt$54.0B$225M
Net debt / EBITDA2.3–
Interest cover4.8×-71.8×

Dividends and buybacks

AMGNZBIO
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$10.08–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or ZBIO

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Zenas BioPharma?

By market value, Amgen ($235B) is about 145.2 times Zenas BioPharma ($1.6B), at today's prices.

How did AMGN and ZBIO stock do over the last 1 years?

Since November 19, 2025, AMGN's price moved +27.2% and ZBIO's -35.8%. With dividends: AMGN +31.5% (+31.5% a year), ZBIO -35.8% (-35.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or ZBIO?

The dividend yield at today's price is 2.31% for Amgen and none for Zenas BioPharma. Over the last twelve months they paid $10.08 and – per share.

Which has the higher profit margins, Amgen or Zenas BioPharma?

Over the last twelve months, the net margin was 24.1% for Amgen and -4,925.5% for Zenas BioPharma, and the operating margin 32.4% and -4,785.5%. Revenue was $38.9B and $11M.

Which is the better investment, Amgen or Zenas BioPharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.